New faculty who joined VP&S in recent months include a specialist in managing infections in immunocompromised patients and a researcher of precision cellular immunotherapies for autoimmunity.
Doctoral students from VP&S and Mailman participated in a university-wide competition designed to help students develop communication skills for future careers. Two shared top honors.
SARS-CoV-2, the virus that causes COVID-19, does not infect brain cells but can inflict significant neurological damage, according to a new study of dozens of deceased patients.
With more patients complaining of lingering and chronic effects from COVID-19, Columbia experts review what’s known and why care for long-haulers requires an interdisciplinary approach.
On Match Day, 154 VP&S students learned where they will start their medical training after graduation and safely celebrated their residencies at a physically distanced event.
A clinical trial to test a gene therapy for some patients with dry age-related macular degeneration—a leading cause of blindness in the United States—is underway at Columbia and NewYork-Presbyterian.
In his book, “Living Cancer,” Columbia oncologist Michael Weiner tells the stories of his patients and reflects on his 360-degree view of cancer as a physician, patient, and parent.